Kategória: Kutatás

Az uniQure bejelentette, hogy folytatják a betegfelvételt a magasabb dózisú AMT-130 vizsgálatba

A Message to the Huntington’s Disease Community from uniQure Dear Huntington’s Disease Community Members, This morning, uniQure issued a press release which included an update on our clinical trial ofAMT-130 […]

A Wave Life Sciences bejelentette az 1b/2a fázisú SELECT-HD kísérlet pozitív eredményeit, amelyek a Huntington-kórban a WVE-003 allélszelektív célpont-elfogadására utalnak.

September 20, 2022 at 7:30 AM EDT PDF Version Single doses of WVE-003 appear generally safe and well-tolerated CSF mutant huntingtin (mHTT) protein was reduced following single doses of 30 […]

Az uniQure bejelentette a Huntington-kór kezelésére szolgáló AMT-130 génterápia I/II. fázisú klinikai vizsgálat alacsony dózisú kohorszának frissítését

~ Treatment generally well-tolerated with no significant safety issues related to AMT-130 in treated patients through one year of follow-up ~ ~ A mean reduction of 53.8% of mutant HTT […]

Az Annexon Biosciences frissíti a vizsgálati eredményeket

ANNEXON BIOSCIENCES REPORTS PHASE 2 CLINICAL TRIAL RESULTS DEMONSTRATING UPSTREAM CLASSICAL COMPLEMENT INHIBITION ASSOCIATED WITH CLINICAL BENEFIT IN HUNTINGTON’S DISEASE On June 7, Annexon, that is a clinical-stage biopharmaceutical company […]

Webinárium - Minden, amit a Proof-HD-ről tudni kell

Yesterday, Prilenia hosted a webinar updating on the Phase III trial with Pridopidine. Thank you to everyone who join and a special thanks to our speakers, Michael Hayden, Andrew Feigin, […]

Breaking News - A Roche új Tominersen tanulmányt tervez

Some encouraging news has just come in from Roche.  Analysis of the results of Roche’s Phase III GENERATION HD1 trial, which was stopped in March 2021, has found that a […]